Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cardiovascular outcomes with SGLT-2i (canagliflozin, empagliflozin, or dapagliflozin) versus metformin in adults with type 2 diabetes (T2D) who initiated first-line treatment

Next Previous
Trial Profile

Cardiovascular outcomes with SGLT-2i (canagliflozin, empagliflozin, or dapagliflozin) versus metformin in adults with type 2 diabetes (T2D) who initiated first-line treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Metformin
  • Indications Cardiovascular disorders; Heart failure; Ischaemic stroke; Myocardial infarction; Type 2 diabetes mellitus
  • Focus Adverse reactions

Most Recent Events

  • 31 May 2022 New trial record
  • 24 May 2022 Results published in the Annals of Internal Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top